retatrutide 2025 trial results produces up to 30.3% weight loss in Phase 3 Investigational weight-loss drug trial shows

The paw withdrawal latency (PWL) to heat was measured after either intraperitoneal or oral gavage administration of glucose (2.0 g/kg body weight) in a volume of 200 L or the same volume of vehicle (0.9% saline) ( n = 5 per group)

More serious but less common adverse effects require clinical vigilance

During dose escalation, when you are moving up to a new, higher dose, temporarily shifting your injection time to the evening (if you normally inject in the morning) can help you tolerate the transition

Most of the trials were conducted in middle- and high-income countries, with little or no representation from regions such as Africa, Central America, and Southeast Asia

After taking GLP-1 weight-loss drugs and finally shedding those excess pounds, some had gone a bit rogue

Dosing mistakes are the most common, and most preventable, problem in peptide research